摘要
目的:探讨银杏二帖葡胺注射液联合吲达帕胺对高血压合并冠心病患者的疗效及血清单核细胞趋化蛋白-1(MCP-1)、心肌型脂肪酸结合蛋白(H-FABP)、可溶性ST2(sST2)的影响。方法:选择2016年2月至2018年2月我院接诊的85例高血压合并冠心病患者进行研究,通过简单随机数表法分为观察组43例和对照组42例。在常规治疗基础上,对照组给予吲达帕胺治疗,观察组在对照组基础上,给予银杏二帖葡胺注射液治疗,连续治疗2个疗程。比较两组降压疗效、心绞痛疗效及中医症候积分、血清MCP-1、H-FABP、sST2的变化和不良反应。结果:两组降压疗效总有效率比较无显著差异(P>0.05);观察组心绞痛疗效总有效率明显高于对照组[90.70%(39/43)vs73.81%(31/42)](P<0.05);治疗后,两组胸痛、气短、心悸证候积分、血清MCP-1、H-FABP、sST2均明显低于治疗前,观察组差值明显大于对照组,差异有统计学意义(P<0.05),且比较均具有交互作用(P<0.05);治疗期间,两组不良反应总发生率分别为9.30%(4/43)和7.14%(3/42),差异无统计学意义(P>0.05)。结论:银杏二帖葡胺注射液联合吲达帕胺治疗高血压合并冠心病患者疗效显著,可有效降低血清MCP-1、H-FABP、sST2的表达,提高心功能,缓解临床症状,且药物安全性高,值得应用推广。
Objective To study the curative effectiveness of ginkgo terpene lactones meglumine injection combined with indapamide in treatment of hypertension coronary heart disease and its effects on the serum monocyte chemoat-tractant protein-1(MCP-1),Heart fatty-acid-binding protein(H-FABP)and soluble ST2(sST2)levels.Methods:85 patients of hypertension complicated with coronary heart disease who received therapy from February 2016 to February 2018 in our hospital were selected as research objects,and with the simple random number table,the patients were divided into the observation group(n=43)and the control group(n=42).On the basis of routine treatment,the control group was treated with indapamide.On the basis of the control group,the observation group was given ginkgo terpene lactones meglumine injection for a continuous treatment of 2 courses.The effect of antihypertensive and angina pectoris and the changes of TCM syndrome score,serum MCP-1,H-FABP and sST2 and adverse reaction were compared between the two groups.Results:There was no significant difference between the two groups in the hypotensive effect(P>0.05);the total effective rate of angina pectoris in the observation group was significantly higher than that of the control group[90.70%(39/43)vs73.81%(31/42)](P<0.05);after treatment,chest pain,shortness of breath,palpitation syndrome score,serum MCP-1,H-FABP and sst2 were significantly lower than before treatment,the difference in the observation group was significantly greater than that in the control group(P<0.05);during treatment,the total incidence of adverse reactions in the two groups was 9.30%(4/43)and 7.14%(3/42)respectively,and the difference was not statistically significant(P>0.05).Conclusion:Ginkgo terpene lactones meglumine injection combined with indapamide is well for hypertension combined with coronary heart disease,which can effectively reduce the expression of serum MCP-1,H-FABP and sST2 levels,improve cardiac function,relieve clinical symptoms,and has high safety,it's worthy of application and
作者
施志红
岳德永
顾立华
樊洪中
SHI Zhihong;YUE Deyong;GU Lihua(Chongming Branch of Xinhua Hospital Affiliated to School of Medicineat Shanghai Jiaotong University, Shanghai 202150, China)
出处
《河北医学》
CAS
2020年第9期1577-1581,共5页
Hebei Medicine
基金
上海市崇明区科委资助项目,(编号:CKY2016-18)。
关键词
高血压
冠心病
吲达帕胺
银杏二帖葡胺注射液
Hypertension
Coronary heart disease
Indapamide
Ginkgo terpene lactones meglumine injection
